Evidence map›Paper›PMID 32612983›Full record

ArticleFrontiers in bioengineering and biotechnology2020

Agrin-Mediated Cardiac Regeneration: Some Open Questions.

Maria Giulia Bigotti, Katie L Skeffington, Ffion P Jones, Massimo Caputo, Andrea Brancaccio

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Signaling pathways regulating cardiac regeneration.Cell regeneration (London, England) · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maria Giulia BigottiBristol Heart Institute, Research Floor Level 7, Bristol Royal Infirmary, Bristol, United Kingdom.
Katie L SkeffingtonBristol Heart Institute, Research Floor Level 7, Bristol Royal Infirmary, Bristol, United Kingdom.
Ffion P JonesBristol Heart Institute, Research Floor Level 7, Bristol Royal Infirmary, Bristol, United Kingdom.
Massimo CaputoBristol Heart Institute, Research Floor Level 7, Bristol Royal Infirmary, Bristol, United Kingdom.
Andrea BrancaccioSchool of Biochemistry, University of Bristol, Bristol, United Kingdom.
Bristol Royal Infirmary · GBIstituto di Scienze e Tecnologie Chimiche "Giulio Natta"

Funding

British Heart Foundation CH/17/1/32804British Heart Foundation PG/15/33/31394
6 · The paper itself

Abstract

After cardiac injury, the mammalian adult heart has a very limited capacity to regenerate, due to the inability of fully differentiated cardiomyocytes (CMs) to efficiently proliferate. This has been directly linked to the extracellular matrix (ECM) surrounding and connecting cardiomyocytes, as its increasing rigidity during heart maturation has a crucial impact over the proliferative capacity of CMs. Very recent studies using mouse models have demonstrated how the ECM protein agrin might promote heart regeneration through CMs de-differentiation and proliferation. In maturing CMs, this proteoglycan would act as an inducer of a specific molecular pathway involving ECM receptor(s) within the transmembrane dystrophin-glycoprotein complex (DGC) as well as intracellular Yap, an effector of the Hippo pathway involved in the replication/regeneration program of CMs. According to the mechanism proposed, during mice heart development agrin gets progressively downregulated and ultimately replaced by other ECM proteins eventually leading to loss of proliferation/ regenerative capacity in mature CMs. Although the role played by the agrin-DGC-YAP axis during human heart development remains still largely to be defined, this scenario opens up fascinating and promising therapeutic avenues. Herein, we discuss the currently available relevant information on this system, with a view to explore how the fundamental understanding of the regenerative potential of this cellular program can be translated into therapeutic treatment of injured human hearts.

Indexed as

agrincardiomyocyte proliferationdystroglycandystrophin-glycoprotein complexheart regenerationHippo pathwaylamininYAP

Identifiers

PMID32612983
PMCPMC7308530
OpenAlexW3034896029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.